Selective in vitro growth of T lymphocytes from normal human bone marrows.

No abstract is available for this paper.

• Publication year

  1976

• Venue

  Science

• Publication date

  1976-09-10

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1126/SCIENCE.181845PMID 181845
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identity of the soluble ebv‐associated antigens of human lymphoid cell lines

  2006cited by this paper
• Long‐Term Maintenance In Vitro of Human T Cells by Repeated Exposure to the Same Stimulator Cells

  1975cited by this paper
• Long-term maintenance in vitro of human T cells by repeated exposure to the same stimulator cells. Differences when using repeated stimulation in allogeneic mixed leukocyte culture and when using stimulation with autologous lymphoblastoid cells.

  1975cited by this paper
• Autologous human B and T lymphoblastoid cell lines

  1974cited by this paper
• Combined detection of human T and B lymphocytes by rosette formation with sheep erythrocytes and zymosan-C3 complexes.

  1974cited by this paper
• Childhood lymphoblastic lymphoma, a cancer of thymus-derived lymphocytes.

  1974cited by this paper
• The presence of the Epstein-Barr viral genome in human lymphoblastoid B-cell lines and its absence in a myeloma cell line.

  1974cited by this paper
• GENERATION OF CYTOTOXIC T LYMPHOCYTES IN VITRO

  1974cited by this paper
• Cellular localization of an Epstein‐Barr virus (EBV)‐associated complement‐fixing antigen in producer and non‐producer lymphoblastoid cell lines

  1973cited by this paper
• Receptors for Complement and Immunoglobulin on Human and Animal Lymphoid Cells

  1973cited by this paper
• Receptors for complement and immunoglobulin on human leukemic cells and human lymphoblastoid cell lines.

  1972cited by this paper
• Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes.

  1972cited by this paper
• Lymphoblastoid cell lines from normal persons and those with nonmalignant diseases.

  1969cited by this paper

• MYC at the tumor–immune interface: mechanisms of immune escape and immunotherapy resistance

  2026cites this paper
• Pharmacological strategies to overcome immune checkpoint inhibitor resistance in non-small cell lung cancer

  2026influential citation
• Cytokines Associated with Activation of CD4+CD25+Foxp3+ T Regulatory Cells.

  2026cites this paper
• IL2Pepscan: A machine learning framework for predicting IL-2 inducing peptides and their identification across global viral proteomes

  2026cites this paper
• Molecular regulation of common γ-chain / Interleukin-2 family cytokine receptors.

  2026cites this paper
• Advances in IL-2 Family Cytokine-Based Cancer Therapies: Overcoming Challenges Through Molecular Engineering and Delivery Strategies.

  2026cites this paper
• CD301b+ dendritic cell-derived IL-2 dictates CD4+ T helper cell differentiation

  2025cites this paper
• Recent advances in adoptive cell therapy for cancer immunotherapy

  2025cites this paper
• The Lasting Impact of IL-2: Approaching 50 Years of Advancing Immune Tolerance, Cancer Immunotherapies, and Autoimmune Diseases

  2025cites this paper
• The dual role of IL-2 in systemic lupus erythematosus: balancing pro-inflammatory and anti-inflammatory effects.

  2025cites this paper
• Side Effects of Immunosuppressant Drugs After Liver Transplant

  2025cites this paper
• BLIMP1 negatively regulates IL-2 signaling in T cells

  2025cites this paper
• Development of a Cell Membrane-Anchored Aptamer Sensor for IL-2 Detection In Situ.

  2025cites this paper
• An immune competent in vitro model of IL2 induced vascular leakage enables mechanistic insights and evaluation of mitigation strategies

  2025cites this paper
• Adoptive T‐cell therapies in the clinic

  2025cites this paper
• Cytokines in Focus: IL-2 and IL-15 in NK Adoptive Cell Cancer Immunotherapy

  2025cites this paper
• A Milestone in the Shift from “Passive Killing” to “Active Immunomodulation” in Cancer Treatment—Progress in Melanoma Vaccine Research

  2025cites this paper
• Enhanced affinity for the IL-2 receptor β subunit potently increases antitumor efficacy of IL-2 across various tumor models by reshaping the tumor microenvironment.

  2025cites this paper
• Engineered Nanobody-Bearing Extracellular Vesicles Enable Precision Trop2 Knockdown in Resistant Breast Cancer

  2025cites this paper
• Elderly female CTLs maintain their initial activation and cytotoxicity independent of IL-2

  2025cites this paper
• OX40L and IL-2 combination strategy for gastric cancer immunotherapy

  2025cites this paper
• Uridine phosphorylase-1 supports metastasis by altering immune and extracellular matrix landscapes

  2025cites this paper
• The role of cytokines in shaping the future of Cancer immunotherapy.

  2025cites this paper
• Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy

  2025cites this paper
• The Multifaceted Role of the IL-2 Cytokine Family in Melanoma: Mechanisms, Therapeutic Implications, and Immune Modulation

  2025cites this paper
• Unlocking T‐Cell Plasticity in the Tumor Microenvironment: Implications for Cancer Progression and Therapeutic Strategies

  2025cites this paper
• The role of IL-2 in type 2 immunity

  2025cites this paper
• Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges

  2025cites this paper
• Neuritin-specific antibody impedes the Treg-mediated suppression of anti-tumor immunity and enhances response to anti-PD1.

  2025cites this paper
• Current landscape and future prospects of interleukin-2 receptor (IL-2R) agonists in cancer immunotherapy

  2025cites this paper
• B-cell editing: An emerging alternative of precision oncotherapy.

  2025cites this paper
• SHR-1916: A Novel PEGylated Interleukin-2 Analogue with Altered Cellular Selectivity and Improved Pharmacokinetic Profiles for Cancer Immunotherapy

  2025cites this paper
• Low dose IL-2 administration prevents but fails to treat experimental autoimmune anti-myeloperoxidase glomerulonephritis.

  2025cites this paper
• Cancer immunotherapy in progress—an overview of the past 130 years

  2025cites this paper
• Mechanistic modeling predicts efficacy of CISH knockout in tumor-infiltrating lymphocytes with synergistic gene editing

  2025cites this paper
• High-efficient refolding and purification of recombinant human interleukin-2 from inclusion bodies.

  2025cites this paper
• Based on the immune system: the role of the IL-2 family in pancreatic disease

  2025cites this paper
• Oncolytic vaccinia virus expressing non-secreted decoy-resistant IL-18 mutein elicits potent antitumor effects with enhanced safety

  2025cites this paper
• Immunocytes in the tumor microenvironment: recent updates and interconnections

  2025cites this paper
• Bifurcation and chaos in tumor-immune dynamics with IL-2: A comparative study of continuous and discrete-time models

  2025cites this paper
• Tumour-infiltrating lymphocyte therapy comes of age in the era of genetic engineering.

  2025cites this paper
• A Roadmap for Predictive Human Immunology

  2025cites this paper
• JAK-STAT pathway, type I/II cytokines, and new potential therapeutic strategy for autoimmune bullous diseases: update on pemphigus vulgaris and bullous pemphigoid

  2025cites this paper
• Targeting γc family cytokines with biologics: current status and future prospects

  2025cites this paper
• Damage-associated molecular patterns in viral infection: potential therapeutic targets

  2024cites this paper
• Artificial antigen-presenting cells: the booster for the obtaining of functional adoptive cells

  2024cites this paper
• Stimulating the Antitumor Immune Response Using Immunocytokines: A Preclinical and Clinical Overview

  2024cites this paper
• Evolución de la inmunoterapia en oncología a través del New England Journal of Medicine

  2024cites this paper
• IL-2 based cancer immunotherapies: an evolving paradigm

  2024cites this paper
• Dual Role of Necroptosis in Cervical Cancer: Promoting Tumor Aggression and Modulating the Immune Microenvironment via the JAK2-STAT3 Pathway

  2024cites this paper
• Influence of Microbiota on Tumor Immunotherapy

  2024cites this paper
• Mathematical model for IL-2-based cancer immunotherapy.

  2024cites this paper
• Elevated levels of IL-12/IL-23p40 in Nova Scotia Duck Tolling Retrievers with autoimmune disease and lymphoma

  2024cites this paper
• Intestinal tissue‐resident memory T cells maintain distinct identity from circulating memory T cells after in vitro restimulation

  2024cites this paper
• Long-lasting mRNA-encoded interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers.

  2024cites this paper
• IL-2 promotes expansion and intratumoral accumulation of tumor infiltrating dendritic cells in pancreatic cancer

  2024cites this paper
• Cantharidin overcomes IL-2Rα signaling-mediated vorinostat resistance in cutaneous T-cell lymphoma through reactive oxygen species

  2024cites this paper
• Targeting cytokine and chemokine signaling pathways for cancer therapy

  2024cites this paper
• Site-specific pegylated IL2 mutein with biased IL2 receptor binding for cancer immunotherapy.

  2024cites this paper
• Unlocking the ‘ova’-coming power: immunotherapy’s role in shaping the future of ovarian cancer treatment

  2024cites this paper
• Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment

  2024cites this paper
• Advances in Vaccines for Melanoma.

  2024cites this paper
• Comparison of IL‐2‐antibody to IL‐2‐Fc with or without stereotactic radiation therapy in CEA immunocompetent mice with CEA positive tumors

  2024cites this paper
• MNK: A Novel Promising Target for Cancer Immunotherapy.

  2024cites this paper
• Uridine Phosphorylase-1 supports metastasis of mammary cancer by altering immune and extracellular matrix landscapes of the lung

  2024cites this paper
• The evolution of cancer immunotherapy: a comprehensive review of its history and current perspectives

  2024cites this paper
• Analyzing IL-2-induced vascular leakage with an irAOP as tool

  2024cites this paper
• Regulating IL-2 immune signaling function via a core allosteric structural network.

  2024cites this paper
• Low‐dose interleukin‐2 for the treatment of systemic lupus erythematosus with recurrent rash

  2024cites this paper
• Revival of recombinant IL-2 therapy – approaches from the past until today

  2024cites this paper
• HIV/AIDS and COVID-19: Shared Lessons from Two Pandemics.

  2024cites this paper
• Interleukin-2 receptor α (IL-2Rα/CD25) shedding is differentially regulated by N- and O-glycosylation.

  2024cites this paper
• Interleukin-2 improves insulin sensitivity through hypothalamic sympathetic activation in obese mice

  2024cites this paper
• Novel design of potent anti-tumour activity of IL-2 prodrug by FAPα-mediated activation.

  2024cites this paper
• Targeting systemic IL-2 to BCMA CAR-T cells

  2024cites this paper
• High-Affinity Fully Human Anti-EpCAM Antibody with Biased IL-2 Exhibits Potent Antitumor Activity

  2024cites this paper
• A novel vesicular stomatitis virus armed with IL-2 mimic for oncolytic therapy

  2024cites this paper
• Evaluation serum soluble interleukin 2 receptor with diagnosis and prognosis in canine solid tumour: 34 cases

  2024cites this paper
• The Assembly of HTLV-1—How Does It Differ from HIV-1?

  2024cites this paper
• Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization

  2024cites this paper
• Nonclinical evaluations of deucravacitinib and Janus kinase inhibitors in homeostatic and inflammatory pathways

  2024cites this paper
• Recent Advances in Molecular Mechanisms of Cancer Immunotherapy

  2023cites this paper
• Transcriptional reprogramming by IL-2 variant generates metabolically active stem-like T cells

  2023cites this paper
• Exploration of the immuno-adjuvant effect and mechanism of Anemoside B4 through network pharmacology and experiment verification.

  2023cites this paper
• Harnessing CD8 T cell responses using PD-1-IL-2 combination therapy.

  2023cites this paper
• Expansion of mixed immune cells using CD3/CD161 co-stimulation for the treatment of cancer

  2023cites this paper
• The T-Cell Growth Factor Interleukin-2, Which Is Occasionally Targeted by Autoantibodies, Qualifies as Drug for the Treatment of Allergy, Autoimmunity, and Cancer: Collegium Internationale Allergologicum (CIA) Update 2024

  2023cites this paper
• Tumor‐infiltrating lymphocyte therapy: Clinical aspects and future developments in this breakthrough cancer treatment

  2023cites this paper
• Rethinking Oncologic Treatment Strategies with Interleukin-2

  2023cites this paper
• Comparison of Pfizer/BioNTech BNT162b2 COVID-19 (Comirnaty) Vaccination Effects in Aged Adults with Special Consideration for the Effectiveness of the Three-Color iSpot in Assessing Immune Response

  2023cites this paper
• The Anticancer Potential of Psidium guajava (Guava) Extracts

  2023cites this paper
• IL-2-loaded Polypeptide Nanoparticles for Enhanced Anti-cancer Immunotherapy

  2023cites this paper
• Crosstalk of Inflammatory Cytokines within the Breast Tumor Microenvironment

  2023cites this paper
• Transcriptomic study of gastrointestinal stromal tumors with liver metastasis

  2023cites this paper
• Targeted Cytokine Delivery for Cancer Treatment: Engineering and Biological Effects

  2023cites this paper
• New sights of low dose IL‐2: Restoration of immune homeostasis for viral infection

  2023cites this paper
• Viremia and Inflammatory Cytokines in Dengue: Interleukin-2 as a Biomarker of Infection, and Interferon-α and -γ as Markers of Primary versus Secondary Infection

  2023cites this paper
• Emerging interleukin targets in the tumour microenvironment: implications for the treatment of gastrointestinal tumours

  2023cites this paper
• Rapid activation of IL-2 receptor signaling by CD301b+ DC-derived IL-2 dictates the outcome of helper T cell differentiation

  2023cites this paper
• Functional T cells are capable of supernumerary cell division and longevity

  2023cites this paper